Drugmakers bid on Bayer's dermatology division

Several drugmakers expressed interest in acquiring Bayer's dermatology business. The Leverkusen, Germany-based company is looking to sell off some of its assets in preparation of its $66 billion acquisition of Monsanto, reported Reuters.

Interested candidates include Canonsburg, Pa.-based Mylan, Ahmedabad, India-based Torrent Pharmaceuticals and Petah Tikva, Israel-based Teva Pharmaceuticals.

Bayer's dermatology products include Desonate, used to treat eczema, and Finacea, a treatment for rosacea. The business could sell for as much as $1.1 billion, according to the report.

More articles on supply chain:

Amgen, Arrowhead Pharma to collaborate on gene-silencing drugs
Uber to develop technology to connect truckers and carriers
CMS warned Mylan about EpiPen rebate issues multiple times

 

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars